The KALRN Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the KALRN gene in the HeLa epithelial cell line. This polyclonal format comprises a heterogeneous pool of cells harboring diverse loss-of-function mutations at the KALRN locus, offering a robust and physiologically relevant model system for investigating Kalirin-dependent signaling without the clonal biases inherent in single-cell-derived knockouts. As a gene-edited product, it enables functional interrogation of Kalirin in a widely used cellular background, facilitating broad experimental applications from mechanistic studies to phenotypic screening.
HeLa cells are an immortalized human cervical adenocarcinoma epithelial cell line originally derived from patient tissue, renowned for their robust growth, ease of culture, and extensive characterization in biomedical research. Their epithelial origin makes them particularly suitable for studying cell adhesion, migration, and cytoskeletal organization. In the context of this knockout model, the HeLa background provides a well-established platform to assess the contributions of Kalirin to actin dynamics and Rho GTPase signaling in a cancer-relevant cellular environment, allowing direct correlation with existing literature and comparative studies.
KALRN encodes Kalirin, a multidomain Rho guanine nucleotide exchange factor (GEF) that catalyzes GDP/GTP exchange on Rho GTPases, predominantly Rac1 and RhoA, thereby orchestrating actin filament remodeling and cell protrusion. Upstream signals, including ephrin receptors, TrkB, and CDK5, regulate Kalirin activity via phosphorylation or second messengers such as calmodulin and 17??-estradiol. Kalirin subsequently activates Rac1 and RhoA, which relay signals through PAK kinases to LIM kinase, culminating in cofilin phosphorylation and stabilization of actin filaments. Additionally, Kalirin forms complexes with DISC1, N-cadherin, and the Arp2/3 complex, spatially coordinating actin nucleation and branching at sites of cell?Ccell adhesion and leading-edge dynamics.
Disruption of KALRN in HeLa cells using a polyclonal knockout strategy yields a loss-of-function model that recapitulates the impairment of cytoskeletal organization observed in Kalirin-deficient systems. In this epithelial context, Kalirin knockout is expected to attenuate Rac1- and RhoA-mediated actin polymerization, leading to reduced cell migration, altered adhesion, and compromised invasion capacity??phenotypes central to cancer metastasis and neurodevelopmental defects. The polyclonal nature ensures that a spectrum of mutations is represented, capturing the functional consequences of Kalirin deficiency more comprehensively than single-clone isolates, which is particularly advantageous for studying dynamic processes like cell motility and for drug discovery screens targeting the Kalirin signaling axis.
This product is ideally suited for a range of research applications, including the investigation of Kalirin??s role in cancer cell invasion and metastasis, detailed dissection of Rho GTPase signaling pathways, and elucidation of cytoskeletal regulation in epithelial cells. Compatible assays include Western blotting and RT-qPCR for expression verification, Rho GTPase activation assays (e.g., GST?CPAK-PBD pull-downs), immunofluorescence for F-actin and focal adhesion markers, and functional assays such as Transwell migration/invasion and cell adhesion assays. The polyclonal format also facilitates high-throughput screening for Kalirin-interacting compounds or pathway modulators. For additional information, custom edits, or knockout validation data, please contact Ascent Research.
